Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 1/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.54 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.53 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25721332 | 0.90 | HPGD (0.54) | P2RY14MRGPRX4RAB9ASMN1; SMN2HDAC8 | |
| SCHEMBL6206631 | 0.87 | MAOB (0.51) | P2RY14MRGPRX4MEN1KMT2ARAB9A | |
| SCHEMBL2932687 | 0.84 | P2RY14 (0.60) | P2RY14MRGPRX4LTB4RLTB4R2MEN1 | |
| SCHEMBL30696120 | 0.83 | MRGPRX4 (0.66) | P2RY14MRGPRX4MEN1KMT2ARAB9A | |
| SCHEMBL6959477 | 0.83 | MRGPRX4 (0.66) | P2RY14MRGPRX4MEN1KMT2ARAB9A | |
| SCHEMBL8130175 | 0.79 | MRGPRX4 (0.55) | P2RY14MRGPRX4MEN1KMT2ANR4A1 | |
| SCHEMBL18397139 | 0.79 | RXRA (0.59) | MRGPRX4MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL11762649 | 0.78 | RXRA (0.61) | MRGPRX4MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL2990559 | 0.78 | KDM4E (0.57) | MRGPRX4RAB9ASMN1; SMN2HDAC8KDM4E | |
| SCHEMBL29375765 | 0.78 | KDM4E (0.57) | MRGPRX4RAB9ASMN1; SMN2HDAC8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023118961-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
| EP-0888301-B1 | MCBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS | SCRIPPS RESEARCH INST (US) | 2005-08-10 | — | — | EP | disclosed |
| EP-0888301-A4 | MCBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS | SCRIPPS RESEARCH INST (US) | 2002-05-08 | — | — | EP | disclosed |
| US-5985908-A | MCBI (7-METHOXY-1,2,9A-TETRA-HYDROCYCLOPROPA(C)BENZ(E)INDOL-4-ONE) IS EMPLOYABLE AS A DNA ALKYLATING AGENT AND CAN BE INCORPORATED INTO ANALOGS OF CC-1065 AND THE DUOCARMYCINS FOR | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0888301-A1 | MCBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS | The Scripps Research Institute (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997032850-A1 | MCBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | CD47, ENPP2, CD2 | P2RY14 3175/4885MRGPRX4 751/4885LTB4R 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.